A landmark UK court ruling clears the way for a major clinical trial testing puberty blockers on 220 young people aged 11 to 16, sparking debate over ethics and safety. Led by King’s College London, the Pathways trial will only include teens who’ve undergone rigorous medical assessments to ensure potential benefit and strict safety protocols. Despite opposition from detransitioners and groups like the Bayswater Group—who argue it lacks ethical rigor—the judge dismissed legal challenges as lacking merit. The trial follows a recent NHS review that questioned evidence in gender medicine and now seeks to fill critical data gaps. Recruitment begins August 1—with participant well-being at the core of every decision.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
